GRI Bio (GRI) Other financing activities (2021 - 2024)

GRI Bio (GRI) posted quarterly Other financing activities of $761000.0 for Q4 2024, up 76000.0% quarter-over-quarter from $1000.0 in Q3 2024.

GRI Bio (GRI) Other financing activities (2021 - 2024) Analysis & Trends

GRI Bio's Other financing activities history runs 2 years deep, the most recent figure standing at $761000.0 for Q4 2024.

In Q4 2024, Other financing activities changed N/A year-over-year to $761000.0; the TTM figure through Dec 2025 stood at $762000.0 (changed 0.0% YoY), while the FY2024 annual figure was $762000.0, up 6250.0% from the prior year.
Other financing activities for Q4 2024 stood at $761000.0, up from $1000.0 in the prior quarter.
The five-year high for Other financing activities was $15.5 million in Q1 2021, with the low at -$15.1 million in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	GRI Bio	3.07 Mn	3.07 Mn	-

Download Data